Rigel Pharmaceuticals
RIGL
96 hedge funds and large institutions have $172M invested in Rigel Pharmaceuticals in 2014 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 23 increasing their positions, 41 reducing their positions, and 18 closing their positions.
13% more capital invested
Capital invested by funds: $153M → $172M (+$19.7M)
8% less funds holding
Funds holding: 104 → 96 (-8)
33% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 18
44% less repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 41
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
+$5.06M |
| 2 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$1.51M |
| 3 |
California Public Employees Retirement System
Sacramento,
California
|
+$1.16M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$735K |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$376K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$2.2M |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$1.55M |
| 3 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$1.54M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.48M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$1.16M |
RIGL Hedge Fund Activity: Q4 2014 in Review
96 of the 3,765 institutional investors tracked by Wall St. Rank reported a position in Rigel Pharmaceuticals (RIGL) for Q4 2014, worth a combined $172M — up 13% from $153M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of RIGL and 12 opened new positions — a net loss of 6 holders — while 41 trimmed existing stakes and 23 added.
The largest buyer was Broadfin Capital, adding an estimated $5.06M. The largest seller was Millennium Management, cutting an estimated $2.2M.
- 96 institutional investors held Rigel Pharmaceuticals (RIGL) as of Q4 2014, down from 104 in Q3 2014.
- Funds reported $172M of Rigel Pharmaceuticals stock for Q4 2014, up 13% quarter-over-quarter.
- 12 funds opened new Rigel Pharmaceuticals positions in Q4 2014 and 18 closed out, a net change of -6 holders.
- The largest Rigel Pharmaceuticals buyer in Q4 2014 was Broadfin Capital, an estimated $5.06M added.
- The largest Rigel Pharmaceuticals seller in Q4 2014 was Millennium Management, an estimated $2.2M sold.
Based on aggregated 13F filings for Q4 2014.